Market Place
Sourcing Support
After sealing reverse merger, Carisma aims for cancer wins
21 Mar 2023 //
FIERCE BIOTECH
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
02 Mar 2023 //
BUSINESSWIRE
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
28 Feb 2023 //
BUSINESSWIRE
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS
21 Feb 2023 //
BUSINESSWIRE
BML Announces Support for Pending Merger with Carisma Therapeutics
15 Feb 2023 //
BUSINESSWIRE
Sesen & Carisma Announce Increased Special Cash Dividend for Pending Merger
14 Feb 2023 //
BUSINESSWIRE
Harvard professor takes on the mantle of Gavi CEO
14 Feb 2023 //
ENDPTS
Sesen Files Investor Presentation in Connection with Pending Carisma Merger
02 Feb 2023 //
BUSINESSWIRE
Sesen Bio Receives NASDAQ Delisting Notice
30 Jan 2023 //
BUSINESSWIRE
Sesen Reiterates Confidence that Merger with Carisma is in Interests of Stockholders
26 Jan 2023 //
BUSINESSWIRE
Spat between Sesen Bio and rival investor group boils over
26 Jan 2023 //
FIERCE BIOTECH
Sesen Files Statement to Stockholders in Connection with Merger with Carisma
19 Jan 2023 //
BUSINESSWIRE
Sesen, Carisma merger plans draw shareholder opposition
05 Jan 2023 //
BIOPHARMADIVE
Sesen Bio & Carisma Therapeutics Announce Substantial Increase to Special Cash
29 Dec 2022 //
BUSINESSWIRE
Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
07 Nov 2022 //
BUSINESSWIRE
Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street
22 Sep 2022 //
BIOPHARMADIVE
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
08 Aug 2022 //
BUSINESS WIRE
Sesen pauses phase 3 bladder cancer program to save cash
19 Jul 2022 //
FIERCEBIOTECH
Sesen Bio reports regulator progress but trial issues linger
09 May 2022 //
FIERCEBIOTECH
Sesen Bio Provides Strategic Update
03 May 2022 //
BUSINESSWIRE
Sesen Bio Reports Q4 and Full-Year 2021 Financial Results and about Vicineum
28 Feb 2022 //
BUSINESSWIRE
Bluebird bio may finally get a gene therapy approved in the US
22 Nov 2021 //
ENDPTS
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
08 Nov 2021 //
BUSINESSWIRE
Sesen Bio Announces Productive CMC Type A Meeting with the FDA
01 Nov 2021 //
YAHOO
Sesen Bio having best day in months as shares rise 26%
13 Oct 2021 //
SEEKINGALPHA
Sesen Bio Expands CMC and Clinical Teams
12 Oct 2021 //
BUSINESSWIRE
Sesen Bio shares crater after report of trial misconduct
19 Aug 2021 //
FIERCEBIOTECH
Sesen regroups after FDA rejection, commercial launch on hold
17 Aug 2021 //
FIERCEPHARMA
Akebia sees first-in-class opening for roxadustat rival: CEO
17 Aug 2021 //
FIERCEPHARMA
Sesen Bio falls again as FDA rejects it`s bladder cancer drug.
16 Aug 2021 //
FIERCEBIOTECH
U.S. FDA declines to approve Sesen Bio`s bladder cancer treatment
14 Aug 2021 //
ENDPTS
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™
13 Aug 2021 //
BUSINESSWIRE
Sesen Bio Reports Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Sesen Bio Partners with EIP for the Commercialization of Vicineumâ„¢ in Turkey
05 Aug 2021 //
BUSINESSWIRE
Sesen Bio Strengthens Leadership Team
02 Aug 2021 //
BUSINESS WIRE
Sesen Bio Announces New Appointments to its Board of Directors
21 Jul 2021 //
BUSINESSWIRE
Sesen Bio and Qilu Announce Enrollment of First Patient for Vicineum
20 Jul 2021 //
BUSINESSWIRE
Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineumâ„¢
14 Jul 2021 //
BUSINESS WIRE
Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineumâ„¢
14 Jul 2021 //
BUSINESS WIRE
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jul 2021 //
BUSINESSWIRE
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Jun 2021 //
BUSINESSWIRE
Sesen Bio Announces Commercial Launch Readiness Progress
04 May 2021 //
BUSINESSWIRE
Sesen Bio to Host Conference Call to Review First Quarter 2021
03 May 2021 //
BUSINESSWIRE
Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application Vicineum™
22 Mar 2021 //
BUSINESSWIRE
Sesen Bio Submits Marketing Authorization Application to the EMA for Vicineum™
08 Mar 2021 //
BUSINESSWIRE
Sesen Bio Submits Marketing Authorization Application to the EMA for Vicineum™
08 Mar 2021 //
PHARMIWEB
Sesen Bio Announces FDA Acceptance and Priority Review of its BLA for Vicineum™
16 Feb 2021 //
BUSINESSWIRE
Sesen Bio Announces FDA Acceptance and Priority Review of its BLA for Vicineum™
16 Feb 2021 //
BUSINESSWIRE
Sesen Bio, after years on the edge of irrelevancy, scores speedy review
16 Feb 2021 //
ENDPTS
Sesen Bio Announces Successful Application Orientation Meeting (AOM)
01 Feb 2021 //
BIOSPACE
Sesen Bio submits Assessment Aid to the FDA for its Vicineum application
19 Jan 2021 //
SEEKINGALPHA
Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™
13 Jan 2021 //
BUSINESSWIRE
Sesen Bio and Qilu Announce IND Application for Vicineum™
13 Jan 2021 //
BUSINESSWIRE
Sesen Bio Submits Completed BLA to the FDA for Vicineum™
21 Dec 2020 //
BUSINESSWIRE
Sesen Bio Submits Completed BLA Application to the FDA for Vicineum™
21 Dec 2020 //
BUSINESSWIRE
Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™
18 Dec 2020 //
BUSINESSWIRE
Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™
18 Dec 2020 //
BUSINESSWIRE
Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™
18 Dec 2020 //
BUSINESSWIRE
Sesen Bio Announces Commercial MFG and Global Supply Partnership with Qilu
07 Dec 2020 //
BUSINESSWIRE
